capital

Market Access

Biotech funding has returned. The bar has moved with it.

For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.

Market Access

Capital discipline in biotech: Building enduring companies w...

Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.

R&D

Female neuroscientist surveys brain scans

From genetic insight to Phase 3: What rare neurology require...

Rare neurology is not defined by a lack of scientific opportunity or capital.

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Market Access

Capital efficient trials in a time of economic uncertainty

In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, pharma and biotech companies should address not just whether a trial

Biotech funding has returned. The bar has moved with it.

Capital discipline in biotech: Building enduring companies w...

From genetic insight to Phase 3: What rare neurology require...

A fast start to 2026 signals continued investor confidence i...

Capital efficient trials in a time of economic uncertainty

Novartis hit as Lp(a) drug fails cardio outcomes trial

Discover a new era of healthcare panel engagement: Grounded ...

capital

Editor's Picks